Report Library
All Reports
Post-ADPD Alzheimer's Disease KOL Interview
April 08, 2015
Key Highlights
For the full report, please download the PDF version at the top of this page.
For our disclosures, please read the BioMedTracker Research Standards. BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
- BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB)
- BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB)
- MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance results in improvement in cognitive decline. (MRK, BIIB)
- There are many permutations of targets for AD, but there is no data that supports one being more efficacious than the other (amyloid antibodies, BACE inhibitors, tau antibodies).
- Current AD symptomatic treatments in Phase III development are "moon shots," but they have supportive Phase II data.
For the full report, please download the PDF version at the top of this page.
For our disclosures, please read the BioMedTracker Research Standards. BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
| Indications Covered: |
Alzheimer's Disease (AD)
Alzheimer's Disease - Imaging Dementia Mild Cognitive Impairment (MCI) |
Additional Resources: